Abstract: Described herein are polymeric nanoparticles that comprise 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]-triazolo-[3,4-fJ[1,6]-naphthyridin-3-one (Compound A), or a pharmaceutically acceptable salt thereof, and methods of making and using such nanoparticles. The nanoparticle comprises about 50 to about 99.8 weight percent of a diblock poly(lactic) acid-poly(ethylene)glycol copolymer or a diblock poly(lactic acid-co-glycolic acid)-poly(ethylene)glycol copolymer, wherein the total amount of poly(ethylene)glycol in the nanoparticle is about 10 to about 30 weight percent poly(ethylene)glycol and about 0.2 to about 30 weight percent of Compound A.
Type:
Application
Filed:
March 12, 2015
Publication date:
March 30, 2017
Applicants:
MERCK SHARP & DOHME CORP., BIND THERAPEUTICS, INC.
Inventors:
Young Ho SUNG, Greg TROIANO, Hong WANG, Maria FIGUEIREDO, Michael H. LAM, Caroline MCGREGOR
Abstract: The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol. Other aspects of the invention include methods of making such nanoparticles.
Type:
Grant
Filed:
May 23, 2012
Date of Patent:
July 19, 2016
Assignee:
BIND Therapeutics, Inc.
Inventors:
Stephen E. Zale, Greg Troiano, Mir Mukkaram Ali, Jeff Hrkach, James Wright
Abstract: The present disclosure generally relates to methods of making nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol.
Type:
Grant
Filed:
January 6, 2014
Date of Patent:
June 28, 2016
Assignee:
BIND Therapeutics, Inc.
Inventors:
Greg Troiano, Michael Figa, Abhimanyu Sabnis
Abstract: The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 1 to about 20 weight percent of a vinca alkaloid; and about 50 to about 99 weight percent biocompatible polymer.
Type:
Grant
Filed:
October 25, 2012
Date of Patent:
May 31, 2016
Assignee:
BIND Therapeutics, Inc.
Inventors:
Stephen E. Zale, Greg Troiano, Mir Mukkaram Ali, Jeff Hrkach, James Wright
Abstract: The present disclosure is directed in part to a biocompatible nanoparticle composition comprising a plurality of non-colloidal long circulating nanoparticles, each comprising a ?-hydroxy polyester-co-polyether and a therapeutic agent, wherein such disclosed compositions provide a therapeutic effect for at least 12 hours.
Type:
Grant
Filed:
July 24, 2012
Date of Patent:
April 12, 2016
Assignee:
BIND Therapeutics, Inc.
Inventors:
Stephen E. Zale, Greg Troiano, Mir M. Ali, Jeff Hrkach, James Wright
Abstract: The present invention generally relates to polymers and macromolecules, in particular, to polymers useful in particles such as nanoparticles. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. In some cases, the nanoparticle may contain a drug. Other aspects of the invention are directed to methods using nanoparticle libraries.
Abstract: The present disclosure relates in part to pharmaceutical compositions comprising polymeric nanoparticles having certain glass transition temperatures. Other aspects of the invention include methods of making such nanoparticles.
Type:
Grant
Filed:
December 15, 2010
Date of Patent:
March 29, 2016
Assignee:
BIND Therapeutics, Inc.
Inventors:
Mir Mukkaram Ali, Abhimanyu Sabnis, David Dewitt, Greg Troiano, James Wright, Maria Figueiredo, Michael Figa, Christina Van Geen Hoven, Young-Ho Song, Jason Auer, Tarikh Christopher Campbell
Abstract: The present disclosure is directed in part to a biocompatible nanoparticle composition comprising a plurality of non-colloidal long circulating nanoparticles, each comprising a ?-hydroxy polyester-co-polyether and a therapeutic agent, wherein such disclosed compositions provide a therapeutic effect for at least 12 hours.
Type:
Grant
Filed:
December 9, 2013
Date of Patent:
December 1, 2015
Assignee:
BIND Therapeutics, Inc.
Inventors:
Stephen E. Zale, Greg Troiano, Mir Mukkaram Ali, Jeff Hrkach, James Wright
Abstract: The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 0.2 to about 20 weight percent of epothilone, e.g. epothilone B; and about 50 to about 99 weight percent biocompatible polymer.
Type:
Application
Filed:
June 14, 2012
Publication date:
April 23, 2015
Applicant:
BIND Therapeutics, Inc.
Inventors:
Maria Figueiredo, David Dewitt, Young-Ho Song
Abstract: The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 0.1 to about 40 weight percent of a therapeutic agent and about 10 to about 90 weight percent a diblock poly(lactic) acid-poly(ethylene)glycol copolymer or a diblock poly(lactic)-co-poly(glycolic) acid-poly(ethylene)glycol copolymer, wherein the diblock poly(lactic) acid-poly(ethylene)glycol copolymer comprises poly(lactic) acid having a number average molecule weight of about 30 kDa to about 90 kDa or the diblock poly(lactic)-co-poly(glycolic) acid-poly(ethylene)glycol copolymer comprises poly(lactic)-co-poly(glycolic) acid having a number average molecule weight of about 30 kDa to about 90 kDa.
Type:
Application
Filed:
October 24, 2011
Publication date:
February 26, 2015
Applicant:
BIND Therapeutics, Inc.
Inventors:
David Dewitt, Maria Figueiredo, Hong Wang, Greg Troiano, Young-Ho Song
Abstract: The present disclosure generally relates to lyophilized pharmaceutical compositions comprising polymeric nanoparticles which, upon reconstitution, have low levels of greater than 10 micron size particles. Other aspects of the invention include methods of making such nanoparticles.
Type:
Grant
Filed:
April 12, 2013
Date of Patent:
February 17, 2015
Assignee:
BIND Therapeutics, Inc.
Inventors:
Greg Troiano, Young-Ho Song, Stephen E. Zale, James Wright, Christina Van Geen Hoven
Abstract: The present disclosure generally relates to lyophilized pharmaceutical compositions comprising polymeric nanoparticles which, upon reconstitution, have low levels of greater than 10 micron size particles. Other aspects of the invention include methods of making such nanoparticles.
Type:
Grant
Filed:
October 30, 2012
Date of Patent:
December 23, 2014
Assignee:
BIND Therapeutics, Inc.
Inventors:
Greg Troiano, Young-Ho Song, Stephen E. Zale, James Wright, Christina Van Geen Hoven
Abstract: The present disclosure relates in part to pharmaceutical compositions comprising polymeric nanoparticles having certain glass transition temperatures. Other aspects of the invention include methods of making such nanoparticles.
Type:
Grant
Filed:
September 27, 2013
Date of Patent:
December 16, 2014
Assignee:
BIND Therapeutics, Inc.
Inventors:
Stephen E. Zale, Greg Troiano, Mir Mukkaram Ali, Jeff Hrkach, James Wright
Abstract: Disclosed herein are therapeutic compositions for treating and preventing diseases such as neointimal hyperplasia (NIH), where the compositions comprise a therapeutic particle that has a localized association with a blood vessel and a therapeutic agent, such as an anti-NIH agent. Methods of use of the therapeutic compositions are also disclosed.
Type:
Grant
Filed:
August 30, 2013
Date of Patent:
December 9, 2014
Assignee:
BIND Therapeutics, Inc.
Inventors:
Amy Grayson, Stephen E. Zale, David Dewitt
Abstract: The present disclosure generally relates to methods of making nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol.
Type:
Application
Filed:
January 6, 2014
Publication date:
December 4, 2014
Applicant:
BIND Therapeutics, Inc.
Inventors:
Greg Troiano, Michael Figa, Abhimanyu Sabnis
Abstract: The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol. Other aspects of the invention include methods of making such nanoparticles.
Abstract: The present disclosure generally relates to nanoparticles comprising a substantially hydrophobic acid, a basic therapeutic agent having a protonatable nitrogen, and a polymer. Other aspects include methods of making and using such nanoparticles.
Type:
Application
Filed:
May 13, 2014
Publication date:
September 4, 2014
Applicant:
BIND Therapeutics, Inc.
Inventors:
Maria Figueiredo, Erick Peeke, David Dewitt, Christina Van Geen Hoven, Greg Troiano, James Wright, Young-Ho Song, Hong Wang
Abstract: The present disclosure generally relates to nanoparticles comprising a substantially hydrophobic acid, a basic therapeutic agent having a protonatable nitrogen, and a polymer. Other aspects include methods of making and using such nanoparticles.
Type:
Application
Filed:
May 13, 2014
Publication date:
September 4, 2014
Applicant:
BIND Therapeutics, Inc.
Inventors:
Maria Figueiredo, Erick Peeke, David Dewitt, Christina Van Geen Hoven, Greg Troiano, James Wright, Young-Ho Song, Hong Wang
Abstract: The present invention generally relates to polymers and macromolecules, in particular, to polymers useful in particles such as nanoparticles. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. In some cases, the nanoparticle may contain a drug. Other aspects of the invention are directed to methods using nanoparticle libraries.